The Experts below are selected from a list of 31137 Experts worldwide ranked by ideXlab platform
Hong Wu - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic effects of a taurine magnesium Coordination Compound on experimental models of type 2 short qt syndrome
Acta Pharmacologica Sinica, 2018Co-Authors: Mengyao An, Yan Li, Yi Kang, Hong WuAbstract:Short QT syndrome (SQTS) is a genetic arrhythmogenic disease that can cause malignant arrhythmia and sudden cardiac death. The current therapies for SQTS have application restrictions. We previously found that Mg· (NH2CH2CH2SO3)2· H2O, a taurine-magnesium Coordination Compound (TMCC) exerted anti-arrhythmic effects with low toxicity. In this study we established 3 different models to assess the potential anti-arrhythmic effects of TMCC on type 2 short QT syndrome (SQT2). In Langendorff guinea pig-perfused hearts, perfusion of pinacidil (20 μmol/L) significantly shortened the QT interval and QTpeak and increased rTp-Te (P<0.05 vs control). Subsequently, perfusion of TMCC (1–4 mmol/L) dose-dependently increased the QT interval and QTpeak (P<0.01 vs pinacidil). TMCC perfusion also reversed the rTp-Te value to the normal range. In guinea pig ventricular myocytes, perfusion of trapidil (1 mmol/L) significantly shortened the action potential duration at 50% (APD50) and 90% repolarization (APD90), which was significantly reversed by TMCC (0.01–1 mmol/L, P<0.05 vs trapidil). In HEK293 cells that stably expressed the outward delayed rectifier potassium channels (IKs), perfusion of TMCC (0.01–1 mmol/L) dose-dependently inhibited the IKs current with an IC50 value of 201.1 μmol/L. The present study provides evidence that TMCC can extend the repolarization period and inhibit the repolarizing current, IKs, thereby representing a therapeutic candidate for ventricular arrhythmia in SQT2.
Mengyao An - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic effects of a taurine magnesium Coordination Compound on experimental models of type 2 short qt syndrome
Acta Pharmacologica Sinica, 2018Co-Authors: Mengyao An, Yan Li, Yi Kang, Hong WuAbstract:Short QT syndrome (SQTS) is a genetic arrhythmogenic disease that can cause malignant arrhythmia and sudden cardiac death. The current therapies for SQTS have application restrictions. We previously found that Mg· (NH2CH2CH2SO3)2· H2O, a taurine-magnesium Coordination Compound (TMCC) exerted anti-arrhythmic effects with low toxicity. In this study we established 3 different models to assess the potential anti-arrhythmic effects of TMCC on type 2 short QT syndrome (SQT2). In Langendorff guinea pig-perfused hearts, perfusion of pinacidil (20 μmol/L) significantly shortened the QT interval and QTpeak and increased rTp-Te (P<0.05 vs control). Subsequently, perfusion of TMCC (1–4 mmol/L) dose-dependently increased the QT interval and QTpeak (P<0.01 vs pinacidil). TMCC perfusion also reversed the rTp-Te value to the normal range. In guinea pig ventricular myocytes, perfusion of trapidil (1 mmol/L) significantly shortened the action potential duration at 50% (APD50) and 90% repolarization (APD90), which was significantly reversed by TMCC (0.01–1 mmol/L, P<0.05 vs trapidil). In HEK293 cells that stably expressed the outward delayed rectifier potassium channels (IKs), perfusion of TMCC (0.01–1 mmol/L) dose-dependently inhibited the IKs current with an IC50 value of 201.1 μmol/L. The present study provides evidence that TMCC can extend the repolarization period and inhibit the repolarizing current, IKs, thereby representing a therapeutic candidate for ventricular arrhythmia in SQT2.
Valeriy Ya Kavun - One of the best experts on this subject based on the ideXlab platform.
-
synthesis and investigation of a new Coordination Compound ammonium octafluoridoindate zirconate heptahydrate nh4inzrf8 7h2o
ChemInform, 2016Co-Authors: Kseniya A Gayvoronskaya, N A Didenko, A B Slobodyuk, A V Gerasimenko, Valeriy Ya KavunAbstract:The title Compound is obtained from an aqueous mixture of ZrO(NO3)2, HF, In(NO3)3, and NH4F (10—12 °C, 2 d).
-
synthesis and investigation of a new Coordination Compound ammonium octafluoridoindate zirconate heptahydrate nh4inzrf8 7h2o
Journal of Fluorine Chemistry, 2015Co-Authors: Kseniya A Gayvoronskaya, N A Didenko, A B Slobodyuk, A V Gerasimenko, Valeriy Ya KavunAbstract:Abstract The synthesis and complex studies (XRD, DTA, IR, and NMR (1H, 19F, including 19F MAS NMR)) of a new Coordination Compound of the composition NH4InZrF8·7H2O have been performed. The structure of NH4InZrF8·7H2O is built from infinite chains [ ZrF 8 In ( H 2 O ) 4 ] 1 − ∞ 1 linked to each other by hydrogen bonds O H⋯F into layers alternating with those consisting of ammonium cations and crystallization H2O molecules. Dehydration of the Compound NH4InZrF8·7H2O proceeds stepwise in the temperature ranges 323–403 K and 403–503 K with formation of NH4InZrF8·H2O and NH4InZrF8, respectively. Anhydrous Compound and monohydrate are characterized with the ability of water absorption from air. Juxtaposition of the 19F MAS NMR spectra of crystal hydrates NH4InZrF8·7H2O and NH4InZrF8·H2O allowed concluding that the monohydrate formation was accompanied by restructuring and formation of a complex anion containing, aside from the terminal Zr Ft bonds, bonds of the same type (In Ft) that were absent in the initial Compound anion.
Yi Kang - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic effects of a taurine magnesium Coordination Compound on experimental models of type 2 short qt syndrome
Acta Pharmacologica Sinica, 2018Co-Authors: Mengyao An, Yan Li, Yi Kang, Hong WuAbstract:Short QT syndrome (SQTS) is a genetic arrhythmogenic disease that can cause malignant arrhythmia and sudden cardiac death. The current therapies for SQTS have application restrictions. We previously found that Mg· (NH2CH2CH2SO3)2· H2O, a taurine-magnesium Coordination Compound (TMCC) exerted anti-arrhythmic effects with low toxicity. In this study we established 3 different models to assess the potential anti-arrhythmic effects of TMCC on type 2 short QT syndrome (SQT2). In Langendorff guinea pig-perfused hearts, perfusion of pinacidil (20 μmol/L) significantly shortened the QT interval and QTpeak and increased rTp-Te (P<0.05 vs control). Subsequently, perfusion of TMCC (1–4 mmol/L) dose-dependently increased the QT interval and QTpeak (P<0.01 vs pinacidil). TMCC perfusion also reversed the rTp-Te value to the normal range. In guinea pig ventricular myocytes, perfusion of trapidil (1 mmol/L) significantly shortened the action potential duration at 50% (APD50) and 90% repolarization (APD90), which was significantly reversed by TMCC (0.01–1 mmol/L, P<0.05 vs trapidil). In HEK293 cells that stably expressed the outward delayed rectifier potassium channels (IKs), perfusion of TMCC (0.01–1 mmol/L) dose-dependently inhibited the IKs current with an IC50 value of 201.1 μmol/L. The present study provides evidence that TMCC can extend the repolarization period and inhibit the repolarizing current, IKs, thereby representing a therapeutic candidate for ventricular arrhythmia in SQT2.
Yan Li - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic effects of a taurine magnesium Coordination Compound on experimental models of type 2 short qt syndrome
Acta Pharmacologica Sinica, 2018Co-Authors: Mengyao An, Yan Li, Yi Kang, Hong WuAbstract:Short QT syndrome (SQTS) is a genetic arrhythmogenic disease that can cause malignant arrhythmia and sudden cardiac death. The current therapies for SQTS have application restrictions. We previously found that Mg· (NH2CH2CH2SO3)2· H2O, a taurine-magnesium Coordination Compound (TMCC) exerted anti-arrhythmic effects with low toxicity. In this study we established 3 different models to assess the potential anti-arrhythmic effects of TMCC on type 2 short QT syndrome (SQT2). In Langendorff guinea pig-perfused hearts, perfusion of pinacidil (20 μmol/L) significantly shortened the QT interval and QTpeak and increased rTp-Te (P<0.05 vs control). Subsequently, perfusion of TMCC (1–4 mmol/L) dose-dependently increased the QT interval and QTpeak (P<0.01 vs pinacidil). TMCC perfusion also reversed the rTp-Te value to the normal range. In guinea pig ventricular myocytes, perfusion of trapidil (1 mmol/L) significantly shortened the action potential duration at 50% (APD50) and 90% repolarization (APD90), which was significantly reversed by TMCC (0.01–1 mmol/L, P<0.05 vs trapidil). In HEK293 cells that stably expressed the outward delayed rectifier potassium channels (IKs), perfusion of TMCC (0.01–1 mmol/L) dose-dependently inhibited the IKs current with an IC50 value of 201.1 μmol/L. The present study provides evidence that TMCC can extend the repolarization period and inhibit the repolarizing current, IKs, thereby representing a therapeutic candidate for ventricular arrhythmia in SQT2.